local lymph node metastases Lymph node oligometastases
Conditions
Interventions
The treatment will consist of online-adaptive SBRT using the ETHOS linear
accelerator. The standard treatment will be 45Gy/5Fx. If the patient anatomy
allows, the number of planned fractions will be
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with abdominal and/or pelvic lymph node recurrences of solid tumors. No more than 5 metastatic lesions in no more than 2 organs and a controlled primary tumor site. Diagnostic imaging includes at least a PET scan or CT thorax/abdomen, of which one is not older than 4 weeks at the time of referral for SBRT. Primary tumor must be treated at least 4 months before the diagnosis of metastasis. Patients must be 18 years or older. Written informed consent
Exclusion criteria
Exclusion criteria: Prior radiotherapy in the same field. Second primary malignancy except in situ carcinoma of the cervix, adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years. Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of the average number of fractions by 30%, by using online adaptive stereotactic radiotherapy for patients with lymph node oligometastases in the abdomen or pelvis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total survival duration, local control, toxicity, bowel movement during treatment via CBCT scans, and the impact of realigning the patient if excessive movement occurs during treatment. | — |
Countries
Netherlands
Outcome results
None listed